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To understand the mechanisms involved in immunological tolerance to skin-associated antigens, we have
developed transgenic (Tg) mice that express a model self-antigen, membrane-bound chicken ovalbumin (OVA),
under the control of a keratin 14 (K14) promoter. K14-mOVA Tg mice express OVA mRNA in the epidermis, and
appear normal. K14-mOVA Tg mice failed to mount T cell and delayed type hypersensitivity reactions to OVA,
suggesting that the Tg mice were tolerant to OVA. Skin dendritic cells, including Langerhans cells, may contribute
to the tolerance induction because migratory skin DC derived from K14-mOVA efﬁciently activated CD8þ T cells
from OVA-speciﬁc T-cell receptor (Va2/Vb5) Tg (OT-I) mice. OT-I cells expanded and accumulated in skin-draining
lymph nodes after intravenous injected into K14-mOVA mice and exhibited activation markers. Graft-versus-host
disease-like skin lesions appeared in K14-mOVA mice by day 7 after injection of OT-I cells. These studies
demonstrate that K14-mOVA Tg mice are susceptible to an autoimmunelike skin disease induced by passively
transferred naı¨ve CD8þ OVA T-cell receptor Tg T cells, and serve as a good model for understanding self-tolerance
and for the investigation of the pathogenesis, treatment and potential prevention of cell-mediated autoimmune
reactions in skin.
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Induction and maintenance of immunological tolerance to
self-antigens is critical for the prevention of autoimmune
diseases. Although the majority of T cells that react with
self-antigens are deleted during thymic differentiation
(Kappler et al, 1987; Kisielow et al, 1988; Pircher et al,
1989), some T cells reactive with peripheral and/or devel-
opmentally regulated self-antigens may escape clonal
deletion and persist in the peripheral circulation. Therefore,
additional regulatory mechanisms must be operative in
order to prevent the activation of such auto-reactive T cells
in peripheral tissues.
Regulatory mechanisms that maintain peripheral toler-
ance include anergy (Schwartz, 1990), immunological igno-
rance (Ohashi et al, 1991), and immune deviation (Zheng
et al, 1999). The relative contributions of each of these to the
maintenance of tolerance to skin-associated antigens are
unknown. Recently, transgenic (Tg) mouse models in which
model self-antigen are expressed in specific tissues have
been developed to investigate the mechanisms underlying
peripheral tolerance. Kurts et al (1996), used a rat insulin
promoter (RIP) to induce tissue-specific expression of a
membrane-bound form of ovalbumin (OVA). In these mice,
OVA expression was induced only in pancreatic cells,
kidney proximal tubular cells, thymus, and testis. In another
study, Vezys et al (2000), used an intestinal fatty acid
binding promoter (iFABP) to induce intracellular OVA
expression in small intestinal enterocytes. The advantage
of studies using OVA as a model self-antigen is the
availability of OVA-specific T-cell receptor (TCR) Tg mice.
If CD8þ OVA TCR Tg T cells were passively transferred into
RIP-OVA or iFABP-OVA Tg mice, Tg T cells were activated
and proliferated in lymph nodes (LN) draining OVA expres-
sing tissues, however, tissue destruction was not observed.
Furthermore, these activated TCR Tg T cells were deleted
after initial activation. Interestingly, if tissue destruction was
induced in these OVA Tg mice by injection with activated
cytotoxic T lymphocytes or infection with vesicular stoma-
titis virus, the passively transferred TCR Tg CD8þ T cells
attack OVA expressing tissue, resulting in autoimmune
reactions.
Skin is the tissue that covers most of the body surface
and works as a barrier against the external environment.
Therefore, immunocompetent cells in the skin (Langerhans
cells (LC), skin homing T cells, etc.) must simultaneously
subserve their roles of inducing protective immunity against
harmful environmental stimuli and in preventing auto-
immune reactions in the skin. To understand the development
and maintenance of peripheral tolerance to skin-associated
antigens, we developed Tg mice (K14-mOVA) that express a
model self-antigen (OVA) under the control of the keratin 14
promoter. After passive transfer of OT-I CD8þ OVA TCR Tg
Abbreviations: CFA, complete Freund’s adjuvant; GVHD, graft-
versus-host disease; K14, keratin 14; LC, Langerhans cells; LN,
lymph node; OVA, ovalbumin; mOVA, membrane bound OVA; TCR,
T-cell receptor; Tg, transgenic
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T cells (without any further activation), these mice develop
graft-versus-host disease (GVHD)-like skin reactions.
Results
Expression of the OVA transgene in K14-mOVA Tg
mice Five Tg mouse lines were established in which mOVA
was expressed under the control of K14 promoter. Both
Southern blot and PCR analysis of genomic DNA confirmed
the integration of the transgene (not shown). Expression
patterns of mRNA in different tissues were analyzed by RT-
PCR. OVA mRNA was detected in skin, but not in other
tissues such as brain, thymus, LN, heart, liver, spleen,
kidney, intestine, skeletal muscles (Fig 1B), or esophagus
(data not shown).
K14-mOVA Tg mice recognize mOVA as a self-antigen To
determine whether K14-mOVA Tg mice were tolerant to
OVA, these mice were immunized with OVA emulsified
with complete Freund’s adjuvant (CFA) by footpad injection
on day 0, and draining LN cells were harvested on day 7
and assessed for proliferative responses to OVA using a
standard in vitro proliferation assay. When control littermate
mice were immunized and challenged with OVA, concen-
tration-dependent T-cell proliferation was observed (Fig 2).
In contrast, K14-mOVA Tg mice demonstrated significantly
lower proliferative responses to OVA. No significant
proliferation was observed either in the Tg or non-Tg mice
if the unrelated antigen, pigeon cytochrome c, was used for
immunization. Tolerance to OVA in K14-mOVA Tg mice was
further assessed by in vivo analysis of their DTH reactions.
Immunization of littermate control mice with OVA emulsified
in CFA resulted in significant footpad swelling if these
animals were challenged with OVA 7 d after priming (Fig 3).
In contrast, K14-mOVA Tg mice immunized with OVA/CFA
developed no significant change in their footpad thickness
(similar to the results in unimmunized K14-mOVA Tg or
littermate control mice). These results indicate that K14-
mOVA mice are tolerant to the model self-antigen OVA.
Homing and activation of passively transferred OT-I
T cells CD8þ T cells were prepared from pooled LN and
spleen cells of OT-I TCR Tg mice, and various numbers of
CD8þ cells were injected via the tail vein into K14-mOVA Tg
Figure 1
Tg construct used in generation of K14-mOVA Tg mice and tissue-
specific expression of mOVA mRNA. (A) A truncated OVA cDNA
(200–1167) and transmembrane domain of PDGFR were placed
downstream of 2.1 kb human K14 promoter region in frame. (B) RT-
PCR analysis demonstrated mOVA mRNA expression in skin. LN,
lymph node; BR, brain; SK, skin; TH, thymus; HR, heart; SP, spleen;
KD, kidney; MS, muscle; IN, intestine; LV, liver; NC, negative control with-
out template; PC, positive control with a plasmid containing Tg
construct; K14, keratin 14; mOVA, membrane-bound OVA; PDGFR,
platelet-derived growth factor receptor; Tg, transgenic.
Figure2
K14-mOVA Tg mice are tolerant to OVA. Priming with OVAþCFA
failed to induce proliferative response of draining LN cells recovered
from K14-mOVA Tg mice. Both K14-mOVA Tg mice and their littermate
control mice were immunized with OVA emulsified with CFA by footpad
injection on day 0, draining LN cells were harvested on day 7, and the
proliferative response of LN cells to OVA was assessed by a standard in
vitro proliferation assay. Concentration-dependent proliferation was
observed in control littermate mice immunized and challenged with
OVA (open squares). In contrast, K14-mOVA Tg mice demonstrated
significantly lower proliferative responses to OVA (closed circles). If
unrelated antigen, pigeon cytochrome c (CC), was used for immuniza-
tion, no significant proliferation was observed in either the K14-OVA Tg
mice (closed triangles) and or in the littermate mice (open diamonds).
K14, keratin 14; mOVA, membrane-bound OVA; Tg, transgenic; CFA,
complete Freund’s adjuvant; LN, lymph nodes.
Figure3
K14-mOVA Tg mice failed to induce DTH response to OVA. Both
K14-mOVA Tg mice and their littermate control mice were subcuta-
neously injected with OVA emulsified with CFA. Seven days later, mice
were challenged with phosphate-buffered saline with or without OVA
into left hind footpads. Significant footpad swelling was observed in
littermate controls immunized with OVAþCFA (closed bar). In contrast,
K14-mOVA Tg mice immunized with OVAþCFA demonstrated no
significant footpad swelling (open bar), which was similar to the result in
non-immunized K14-mOVA mice (hatched bar) or non-immunized
littermate controls (gray bar). Data indicates an average and standard
deviation of ten animals in each group. K14, keratin 14; mOVA,
membrane-bound OVA; Tg, transgenic; DTH, delayed-type hypersen-
sitivity; CFA, complete Freund’s adjuvant.
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mice or into littermate control mice (Kurts et al, 1996). At 2,
4, 7 and 21 d after passive transfer of 5  106, draining
superficial LN cells were harvested and analyzed for the
presence of OT-I cells. As early as 4 d after the transfer,
Va2þ Vb5þ Tg T cells accumulated in the LN draining skin
(Figs 4 and 5A). When the phenotype of Va2þ Vb5þ Tg T
cells in K14-mOVA Tg LN was assessed transferred Tg T
cells exhibited a CD25þ CD44bright CD62Ldim activated
phenotye (Fig 5B). In contrast, OT-I Tg T cells transferred
into littermate control mice showed CD25 CD44dim
CD62Lbright resting phenotype (data not shown). A time
course analysis demonstrated that OT-I T cells in K14-
mOVA Tg mice started to accumulate in regional LN on day
4, further expanded on day 7, and returned to a baseline
level (as in littermate control mice), resulting in no significant
accumulation of OT-I T cells in LN on day 21 (Fig 4).
Thus, transferred OVA-specific OT-I cells recognize OVA
antigen in K14-mOVA Tg mice, but not in their littermate
control mice.
Development of GVHD-like skin disease following OT-I
T-cell transfer Following the activation of OT-I T cells in
regional LN, K14-mOVA Tg mice developed acute inflam-
matory skin lesions starting on day 5 (Fig 6C and D); 5  106
cells regularly induced GVHD-like reactions, whereas
1  106 cells induced lesser changes and 5  105 cells
did not induce GVHD-like reactions. Footpads and ear skin
became erythematous and swollen. Footpad swelling was
most intense from days 7 to 11, and started to wane on day
12 (Fig 6E). Histopathological examination of the dorsum
of the feet on day 7 revealed severe dermal edema and
mononuclear cell infiltration in K14-mOVA Tg mice (Fig 6D).
A thickened epidermis, exocytosis, dyskeratotic cells, and
dermal inflammation were also seen when footpads were
examined (Fig 7). A similar inflammatory reaction was also
observed in the esophagus (Fig 8A and B). In addition to
the skin and esophageal lesions, the spleen was slightly
enlarged, and the thymus was markedly decreased in size.
No significant inflammatory reaction was observed in other
tissues including brain, lung, heart, liver, intestine, kidney,
and skeletal muscles (data not shown). Control littermate
mice transferred with OT-I T cells did not exhibit inflamma-
tory skin lesions after transfer of cells (Fig 6A and C).
K14-mOVA mice progressively lost body weight resulting in
about 20%–30% loss by day 14 (Fig 9A). The majority of the
K14-mOVA Tg mice, but not their littermate controls, died
between 14 and 21 d after passive transfer (data not
shown). Death is probably due to the inflammation that is
seen around the mouth and in the esophagus, which makes
it difficult or impossible for the mice to eat and drink. If K14-
mOVA Tg mice were examined 21 d after transfer, these
animals showed erythematous scaly macules and less hair
Figure 4
Kinetics of accumulation of OT-I cells in lymph node (LN) after
passive transfer. At 2, 4, 7, and 21 d after passive transfer, draining
superficial LN cells were analyzed for the accumulation of OT-I cells. At
7 d after the transfer, 90% of CD8 T cells were OT-I cells in LN of K14-
mOVA mice (closed circles). In all, 2%–3% of CD8 T cells were OT-I
cells in littermate mice that were infused with OT-I cells (open circles).
Figure 5
OT-I T cells passively transferred into K14-
mOVA Tg mice expanded and expressed
activation markers. FACS profiles showing: (A)
Draining superficial lymph node cells from K14-
mOVA Tg and littermate control mice were
analyzed for the presence of OT-I cells (Va2þ
Vb5þ CD8 T cells). At 4 d after the cells transfer,
OT-I cells accumulated in the LN draining skin
in K14-mOVA mice (43.2% positive for Va2þ
Vb5þ ), but not in littermate controls (1.8%
positive for Va2þ Vb5þ ). (B) When the pheno-
type of Va2þ Vb5þ CD8 T cells in the superficial
LN of OVA Tg mice was analyzed, OT-I cells
demonstrated a CD25þ CD44bright CD62Ldim
activated phenotype. In contrast, when the
phenotype of Va2þ Vb5þ CD8 T cells in the
superficial LN of littermate mice was analyzed,
these T cells showed a CD25 CD44dim
CD62Lbright resting phenotype (data not shown).
K14, keratin 14; mOVA, membrane-bound OVA;
Tg, transgenic; LN, lymph node.
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on their face and feet (Fig 9B). Histologically, K14-mOVA
mice demonstrated hyperkeratosis, scattered dyskeratotic
cells, mild mononuclear cell infiltration, and marked
sclerotic change in the dermis, similar to chronic GVHD
skin lesions (Fig 9D).
Migratory DC from K14-mOVA Tg mice induce prolifera-
tion of OT-I T cells To determine whether LC from K14-
mOVA mice were capable of presenting OVA to OT-I CD8þ
T cells, migratory dendritic cells were obtained 3 d after
culture of ear skin. Unpulsed LC derived from normal B6
skin explant failed to induce proliferation of OT-I T cells
(Fig 10). In contrast, unpulsed LC derived from K14-mOVA
Tg skin explant induced significant concentration-depen-
dent proliferation of OT-I T cells. These data indicate that
OVA protein produced by K14-mOVA Tg keratinocyte is
delivered to LC for the cross-presentation of OVA peptide in
the context of class I major histocompatibility complex
(MHC) molecules. Thus, tolerance observed in K14-mOVA
Tg mouse may be due to the presentation of OVA antigen by
LC migrating to the regional LN during the development of
their immune systems.
Discussion
In this study, we demonstrated that skin-directed expres-
sion of a model self-antigen, OVA, is induced in Tg mice by
using human K14 promoter and GVHD-like inflammatory
skin disease developed by transferring OVA-specific OT-I
CD8þ T cells.
Tg mouse models have been used as tools to investigate
the mechanisms involved in peripheral tolerance. Early
studies using tissue-specific expression of allogenic MHC
class I (Miller et al, 1990; Schonrich et al, 1991) and class II
(Lo et al, 1988; Sarvetnick et al, 1988; Bohme et al, 1989;
Lo et al, 1989; Miller et al, 1990) molecules demonstrated
functional peripheral tolerance in vivo. Mice expressing
model self-antigens such as lymphocytic choriomeningitis
virus (LCMV) nucleoprotein, LCMV glycoprotein (Oldstone
et al, 1991; Lo et al, 1992; Ohashi et al, 1993; Morgan et al,
1999) or influenza virus hemagglutinin (Roman et al, 1990)
under the control of an insulin promoter did not exhibit
autoimmunity, unless they were infected with the respective
virus. In accordance with these previous studies, no
significant inflammatory reaction was observed in K14-
mOVA mice even after the immunization with OVAþCFA.
Furthermore, lymphocytes recovered from OVA immunized
K14-mOVA mice demonstrated significantly reduced pro-
liferative responses to OVA. These data indicate that
antigen-specific tolerance is induced in OVA reactive lym-
phocytes either by clonal deletion during development or by
the regulatory mechanisms operating in peripheral tissues
(Oldstone et al, 1991; Ohashi et al, 1993). Interestingly,
Figure 6
K14-mOVA Tg mice, but not their littermate control mice, devel-
oped acute inflammatory skin lesions after OT-I T cell transfer. OT-I
cells were injected via the tail vein into K14-mOVA Tg mice or into
littermate control mice. Footpad swelling developed as early as 5 d
after transfer, became maximum on days 7–11 (compare (A) littermate
control with (C) K14-mOVA mouse) and then decreased on day 12 (E).
Histopathologic analysis of dorsum of the feet of the K14-mOVA Tg 7 d
after i.v. injection of OT-I cells showed vasodilation, mononuclear cell
infiltration, and severe dermal edema (D) as compared with littermate
control mice (after injection of OT-I cells) where no significant patho-
logic reaction was observed (B). K14, keratin 14; mOVA, membrane-
bound OVA; Tg, transgenic.
Figure 7
Graft-versus-host disease-like histology in the
footpads of K14-mOVA mice after i.v. injection
of OT-I cells. Histology of the footpad of normal
C57BL/6 mice (A) and of K14-mOVA mice (B) 14 d
after injection of 5  106 OT-I cells. The K14-mOVA
mice show a thickened epidermis, exocytosis,
dyskeratotic keratinocytes, and dermal inflamma-
tion. K14, keratin 14; mOVA, membrane-bound
OVA.
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inflammatory skin reactions and tissue destruction were
induced by simply transferring OT-I T cells without any
further activation in our model. In prior studies using OVA as
a model self-antigen (Kurts et al, 1996; Vezys et al, 2000),
passively transferred OT-I T cells accumulated in the OVA
expressing tissues and draining LN, and demonstrated an
activated phenotype and proliferate in the LN, however, no
pathogenic inflammatory reaction developed in OVA ex-
pressing tissues (Kurts et al, 1996; Vezys et al, 2000).
Furthermore, transferred OT-I T cells were deleted (Kurts
et al, 1997) or became anergic (Vezys et al, 2000) in these
studies. Although we do not know the reason for this
discrepancy, the presence of antigen-laden LC may result in
the development of the inflammatory reactions seen in our
K14-mOVA Tg mouse model. LC are bone marrow-derived
antigen-presenting cells uniquely located within the epider-
mis (Katz et al, 1979). LC work as sentinels in skin and
subserve an important role in T-cell-mediated skin diseases,
such as contact dermatitis (Tamaki et al, 1981) and atopic
dermatitis (Taylor et al, 1991). In GVHD, it is well known that
epidermal LC disappear from the skin lesion (Lampert et al,
1982; Aractingi et al, 1997), suggesting their activation and
migration to the regional LN. In our model system,
expansion of OT-I cells began on day 4 and then the
swelling of the footpads and ears and histological changes
occurred starting on days 6–7 and LC decreased in density
from the epidermis when these K14-mOVA Tg mice were
analyzed 7–10 d after OT-I T-cell transfer (data not shown). It
has been previously demonstrated that DC can internalize
soluble proteins or acquire antigen from apoptotic cells, and
subsequently can activate class I restricted CD8þ cytotoxic
T lymphocytes via a mechanism termed cross-priming
(Brossart and Bevan, 1997; Albert et al, 1998). Consistent
with these previous studies, migratory LC derived from K14-
mOVA skin explants efficiently activated CD8þ OT-I T cells.
Activated OT-I T cells may then attack OVA expressing
epidermis and further enhance activation and migration of
LC to the regional LN. Importantly, when we injected OT-I
cells locally into the ears or footpads of K14-mOVA mice, no
significant skin reaction ensued as determined histologically
(data not shown). This supports the concept that cells need
to be activated through interaction with antigen-presenting
cells in the LN.
In summary, we have established a new Tg mouse model
system in which T-cell-mediated autoimmune skin reaction
can be induced by transferring TCR Tg mouse T cells.
Although we do not know the underlying mechanisms by
which autoimmune skin disease could be induced in our
Figure 8
Esophagus of K14-mOVA mice show submu-
cosal inflammation 7 d after i.v. injection
of OT-I T cell transfer. Marked inflammation of
the esophagus of K14-mOVA mice (B) ensues
7 d after OT-I T cell transfer (compare with (A)
esophagus of normal C57BL/6 mice after i.v.
injection of OT-I T cells). K14, keratin 14; mOVA,
membrane-bound OVA.
Figure 9
Progressive weight loss and chronic graft-
versus-host disease-like skin lesions devel-
oped in K14-mOVA Tg mice after OT-I T cell
transfer. (A) K14-OVA mice, but not their litter-
mate control mice, progressively lost their body
weight after transfer of the OT-I cells, resulting
in about 20%–30% loss on day 14. (B) Gradually
K14-mOVA Tg mice lost hair with mechanical
rubbing and showed scaly lesions and were small
compared with littermate mice. (C) littermate
control and (D) K14-mOVA mouse. Histopatho-
logy showed marked hyperkeratosis, dyskerato-
sis, and severe dermal fibrosis in K14-mOVA Tg
mice 21 d after OT-I Tcell transfer. K14, keratin 14;
mOVA, membrane-bound OVA; Tg, transgenic.
GVHD-LIKE SKIN DISEASE IN K14-mOVA Tg MICE 113123 : 1 JULY 2004
system, this Tg mouse model will be useful to investigate
both the induction and loss of peripheral tolerance, and
to test potential therapeutic agents for the treatment of
autoimmune diseases.
Materials and Methods
Mice All mice were obtained from the National Cancer Institute
Animal Production Program (Frederick, Maryland), housed in a
clean (not pathogen-free) facility that does not allow MHV or
pinworms, bred, and used in accordance with institutional guide-
lines. OVA-specific class I restricted TCR Tg mice (OT-I) (Hogquist
et al, 1994) were obtained from Dr Judy Kapp (Emory University,
Atlanta, Georgia).
Construction of transgene and generation of Tg mouse
lineages The plasmid pK14-mOVA was constructed as follows.
OVA cDNA fragment (200–1167) was amplified from the TC-OVA
plasmid (Lim et al, 1998) by PCR, using primers containing unique
BgIII and SacII sites in their 50 upstream and 30 downstream
sequences, respectively. The amplified PCR product was cloned
into unique BgIII and SacII sites of the pDisplay expression vector
(Invitrogen, Carlsbad, California) in frame to make a fusion protein
that consisted of the murine immunoglobulin k chain V-J2-C signal
peptide, the OVA fragment (200–1167), and the transmembrane
domain of platelet-derived growth factor receptor (PDGFR) (Fig 1A).
To induce transgene expression under the control of the K14
promoter, the cytomegalovirus promoter of a pCMBb mammalian
reporter vector (Clontech, Palo Alto, California) was excised with
EcoR1 and XhoI (New England Biolabs, Beverly, Massachusetts),
and replaced with a 2.1 kb human K14 promoter. Then, the vector
sequence encoding b galactosidase was excised with NotI (New
England Biolabs), and replaced with the membrane-bound OVA
(mOVA) fusion protein construct, which was excised by digestion
with EagI (New England Labs). The construct was sequenced to
verify authenticity of the mOVA fusion protein open reading frames
and the junction of the K14 promoter to the mOVA sequence. For
microinjection of the transgene, the Tg vector sequence was
excised with KasI and HindIII (New England Biolabs), purified by
gel electrophoresis, and microinjected into the pronuclei of C57BL/
6 fertilized eggs. Transgene integration in founder mice was
screened by Southern blot and PCR analysis of genomic DNA
prepared from tail biopsies.
RT-PCR analysis of transgene expression Total RNA was
prepared from various tissues including brain, thymus, lung, heart,
liver, intestine, kidney, muscle, skin, esophagus, spleen, and LN
using TriZol (Lifetechnology, Rockville, Maryland) according to
the manufacture’s protocol. The total RNA preparation was re-
verse transcribed using a random hexamer (Roche, Foster
City, California), and used as a template for the PCR reaction.
Contaminating genomic DNA was digested with DNase I (Life-
technology) before reverse transcription. 50 (TTCCAGGATTCGGA-
GACAGTATTG) and 30 (TCATCAGGCAACAGCACCAAC) primers
were used to amplify the mOVA fragment, which was detected on
a 1.2% agarose gel containing ethidium bromide. All reagents for
RT-PCR were purchased from Lifetechnology unless otherwise
indicated.
Proliferation assays K14-mOVA Tg mice and littermate control
mice were injected with 50 mL (2 mg per mL) of OVA (Sigma, St
Louis, Missouri) emulsified with complete Freund’s adjuvant (CFA)
(Difco Laboratories, Detroit, Michigan) into one footpad. Seven
days later, single cell suspensions were prepared from draining LN
with complete RPMI (RPMI 1640) supplemented with 10% FCS
(Biofluids, Rockville, Maryland), 2 mM L-glutamine, 0.1 mM non-
essential amino acids, 1 mM sodium pyruvate, 1% antibiotic–
antimycotic, 10 mM HEPES (Lifetechnologies, Grand Island, New
York) and 50 mM 2-ME (Sigma Chemical Co., St Louis, Missouri)
using standard techniques. A total of 3  105 cells per well were
added to 96-well flat-bottom tissue culture plates with or without
various concentrations of OVA and cultured for 4 d. A measure of 1
mCi [3H]thymidine was added to each well during the last 18 h of
culture period. At the end of the culture period, cells were
harvested and cell-associated radioactivity was counted by direct
b counting using a gas ionization counter (Packard, Meriden, CN).
Delayed-type hypersensitivity (DTH) reaction K14-mOVA Tg
mice and littermate control mice were subcutaneously injected
with 50 mL of OVA emulsified with CFA onto the both lateral
aspects of the lower abdominal area. Seven days later, mice were
challenged with a subcutaneous injection of 40 mL of phosphate-
buffered saline (PBS) with, or without, OVA (2 mg per mL) into the
left hind footpad and changes in footpad thickness at 24 and 48 h
after challenge were determined using the technique of Matsu et al,
1999.
Preparation and passive transfer of OT-I T cells Single cell
suspensions were prepared from pooled spleens and LN of OT-I
mice, and resuspended in complete RPMI. CD8þ T cells were
purified using CD8 columns (R&D Systems, Minneapolis, Minne-
sota) according to the manufacturer’s protocol. FACS analysis of
purified samples demonstrated greater than 98% purity of CD8þ
cells. In all, 5–10  106 cells were resuspended in PBS and
injected intravenously (i.v.) into K14-mOVA or control littermate
mice. Body weight and footpad swelling were measured in both
groups at various times after injection.
FACS analysis of K14-mOVA Tg mice after passive transfer At
various time points, single cell suspensions were prepared from
thymus, spleen, and LN of K14-mOVA Tg mice or littermate control
mice that were injected i.v. with OT-I CD8þ T cells. Expression of
surface molecules was quantified by flow cytometry using the
following monoclonal antibodies (mAb); FITC-conjugated anti-Va2,
bioitin-conjugated anti-Vb5, PE-conjugated anti-CD25, anti-CD44,
anti-CD62L, or appropriate isotype-matched control mAb (Phar-
mingen). APC-conjugated streptavidin (Pharmingen, San Diego,
California) was used for the visualization of biotin-conjugated mAb.
Staining was performed according to standard techniques as
Figure 10
Migratory LC prepared from K14-mOVA Tg skin explants induce
expansion of OT-I Tcells. Migratory LC were prepared from normal B6
or K14-mOVA Tg mice and used as stimulator cells. Unpulsed LC
derived from normal B6 skin explant failed to induce proliferation of OT-
I T cells (closed squares). In contrast, unpulsed LC derived from K14-
mOVA Tg skin explants (open diamonds) and LC derived from normal
B6 mice that are OVA-peptide pulsed (open circles) induced significant
concentration-dependent proliferation of OT-I cells. LC, Langerhans
cells; K14, keratin 14; mOVA, membrane-bound OVA; Tg, transgenic.
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previously described and cells were analyzed with a FACSCalibur
using Cell Quest software.
Mixed lymphocyte reaction Single cell suspensions were pre-
pared from pooled spleens and LN of OT-I mice, and resuspended
in complete RPMI. CD8þ T cells were purified using CD8 columns
(R&D Systems). LN DC were isolated using a modification of a
previously described method (Vremec et al, 1992). Pooled LN were
teased and treated with collagenase (1 mg per mL) and DNase
(0.02 mg per mL) (Sigma) at room temperature for 30 min with
EDTA treatment during the last 5 min. Light density fractions were
selected by centrifugation with 14.5% metrizamide (Sigma) at 1700
G. Interface cells were recovered and resuspended in complete
RPMI for further use; 1.5  105 OT-I cells were co-cultured with
various numbers of stimulator cells in 96-well flat-bottom tissue
culture plates in complete RPMI for 4 d. Skin-derived DC (migra-
tory LC) were isolated by methods published previously (Larsen
et al, 1990) after 3 d of culture in complete RPMI. In all, 1.5  105
OT-I T cells were co-cultured with various numbers of stimulator
cells in 96-well flat-bottom tissue culture plates in complete RPMI
for 2 d and 16 h. During the last 16 h of culture period,
[3H]thymidine was added (1 mCi per well) and cell-associated
radioactivity was counted by direct b counting as described.
Histological analysis Tissue samples were prepared from K14-
mOVA Tg mice at various times after passive transfer of OT-I cells
and fixed in 10% neutral-buffered formalin. Paraffin embedded
tissues were sectioned and stained with hematoxylin and eosin
using standard techniques (American Histolabs, Rockville, Mary-
land).
Statistical analysis The Student t test was used. Differences
were considered significant if po0.05.
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